RetinaCME
EXPERT VIDEOCMEABO MOC

Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Extending the Duration of Therapy

Author(s)/Faculty: Rishi P. Singh, MD; Nancy M. Holekamp, MD; Michael A. Singer, MD
Release Date: 4/30/2021Expiration Date: 4/29/2022
Credit Type: CME / CME with ABO Continuing Certification Number of Credits: 1
Content Type: VideoProvider:
Treatment burden and subsequent loss of patient adherence are significant factors associated with less-than-optimal visual acuity gains seen in real-world outcomes in patients with neovascular retinal diseases. Ongoing clinical studies are evaluating novel delivery systems, gene therapies, and agents that enhance dosing intervals while targeting novel pathways with the potential to reduce treatment burden and improve visual acuity outcomes. In this educational activity, Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases – Session on Extending the Duration of Therapy, experts in the field review the treatment burden observed with current therapies; examine the role of persistent retinal fluid in determining response to treatment; as well as evaluate new and emerging agents that may reduce the burden of anti-vascular endothelial growth factor (VEGF) therapy in neovascular retinal diseases.